Atikah Kamaruddin, senior research executive, Ipsos Immunology Monitors Cardiometabolic/ Cardiovascular Drug: CagriSema Company: Novo Nordisk Indication: Obesity Stage: Phase III Background: CagriSema is Novo Nordisks next-generation obesity therapy combining two separate drugs, cagrilintide (amylin analog) plus GLP-1 semaglutide
however, its misuse for weight loss is also increasing
For many people, that means combining evidence-based treatment with ongoing support that helps healthy changes become sustainable
More recent trials have associated oral propionyl-L-carnitine supplementation (2 g/day for several months) with improved walking distance and claudication onset time (66, 67), as well as with higher pain-free walking distance and higher ankle-brachial index (a diagnostic measure of peripheral arterial disease) (68)
The sex-specific associations were mostly based on the UK Biobank, which also need replication in other data sources when available